Table 1.
ID8b (FR+++) | MX-1c (FR++) | L1210-FRd (FR++) | WI-38e (FR−) | |
---|---|---|---|---|
Paclitaxelf | 13.8 ± 2.7 | 5.59 ± 2.12 | 27.6 ± 7.5 | 55.7 ± 9.5 |
SB-T-1214f | 2.82 ± 0.70 | 1.89 ± 0.80 | 2.66 ± 1.33 | 4.89 ± 2.24 |
1f | 2.52 ± 1.50 | 3.43 ± 2.23 | 3.51 ± 1.16 | > 5,000 |
1g (GSH-OEt) | N.D.i | 2.08 ± 1.30 | 3.35 ± 2.00 | N.D.i |
1h (GSH) | N.D.i | 3.42 ± 2.98 | 3.87 ± 2.61 | N.D.i |
IC50: concentration required for 50% growth inhibition;
murine ovarian cancer cell line (FR+++);
human breast cancer cell line (FR++);
murine leukemia cell line (FR++);
human lung fibroblasts (normal) cell line (FR−);
Cells were incubated with each drug for 72 h.;
After cells were treated with 1 for 24 h, GSH-OEt (6 equiv.) was added and then incubated for another 48 h (Total 72 h);
After cells were treated with 1 for 24 h, GSH (6 equiv.) was added, and then incubated for another 48 h (total 72 h).
Not determined.